Assessing the clinical significance of drug interactions with fluorouracil in patients with colorectal cancer

American Journal of Health-System Pharmacy

Volumn 62, Issue 17, 2005, Pages 1788-1793

  Jansman, Frank G A ^a,e   Jansen, Anita J A ^a   Coenen, Jules L L ^a   De Graaf, Jacques C ^a   Smit, Willem M ^b   Sleijfer, Dirk T ^c   Brouwers, Jacobus R B ^d  

^a ISALA HOSPITAL   (Netherlands)

^b MEDISCH SPECTRUM TWENTE   (Netherlands)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^d UNIVERSITY OF GRONINGEN   (Netherlands)

^e UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; ALPHA2A INTERFERON; ALPHA2B INTERFERON; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANALGESIC AGENT; ANTIDIARRHEAL AGENT; ANTIEMETIC AGENT; CIMETIDINE; CYTOTOXIC AGENT; DIPYRIDAMOLE; FLUOROURACIL; FOLIC ACID; FOLINIC ACID; HYDROCHLOROTHIAZIDE; HYDROCORTISONE; LEVAMISOLE; METRONIDAZOLE; MISONIDAZOLE; PHENYTOIN; PYRIDOXINE; SORIVUDINE; TAMOXIFEN; THALIDOMIDE; THIAZIDE DIURETIC AGENT; WARFARIN;

ANEMIA; ARTICLE; BLOOD TOXICITY; COLORECTAL CANCER; CONJUNCTIVITIS; CONTROLLED STUDY; DIARRHEA; DRUG CROSS REACTIVITY; DRUG CYTOTOXICITY; FATIGUE; FEMALE; GOOD CLINICAL PRACTICE; HAND FOOT SYNDROME; HUMAN; LEUKOPENIA; MALE; MUCOSA INFLAMMATION; NAUSEA; PRIORITY JOURNAL; VOMITING;

EID: 24144497985     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp040584     Document Type: Article

References (60)

1. Bernard SA, Bruera E. Drug interactions in palliative care. J Clin Oncol. 2000; 18:1780-99.
2. Corcoran ME. Polypharmacy in the older patient with cancer. Cancer Control 1997; 4:419-28.
3. Delafuente JC. Understanding and preventing drug interactions in elderly patients. Crit Rev Oncol Hematol. 2003; 48:133-43.
4. WHO Collaborating Centre for Drug Statistics. Guidelines for ATC classification and DDD assignment. www.whocc.no (accessed 2004 Dec 1).
5. National Cancer Institute. International Common Toxicity Criteria. www. ctep.info.nih.gov/CTC3default.htm (accessed 2004 Dec 1).
6. Jansman FG, Coenen JL, de Graaf JC et al. Relationship between pharmacokinetics of 5-FU in plasma and in saliva, and toxicity of 5-fluorouracil/folinic acid. Anticancer Res. 2002; 22:3449-56.
7. Tatro DS. Drug interaction facts. St Louis: Facts and Comparisons; 2004.
8. Sjoqvist F. FASS 2000. Stockholm: LINFO Drug Information; 2000:1481-6.
9. Hansten PD, Horn JR. Drug interactions. St. Louis: Facts and Comparisons; 2001.
10. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977; 33:159-74.
11. Poon MA, O' Connell MJ, Moertel CG et al. Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol. 1989; 7:1407-17.
12. Laufman LR, Krzeczowski KA, Roach R et al. Leucovorin plus 5-fluorouracil: an effective treatment for metastatic colon cancer. J Clin Oncol. 1987; 5:1394-400.
13. Stockley IH. Stockley's drug interactions. 6th ed. London: Pharmaceutical Press; 2002.
14. Note for guidance on the investigation of drug interactions. London: EMEA/CPMP; 1997.
15. Illiger HJ, Bornmann L, Herdrich K. Drug interactions in the therapy of malignant diseases. Munich, Germany: ASTA Medica Oncology; 2001.
16. Drugdex drug evaluations. Fluorouracil monograph. Healthcare Series vol. 121. Expires 2004 Sep.
17. Summary of product characteristics 5-fluorouracil. Mijdrecht, The Netherlands: Teva Pharma BV; 2003 Nov.
18. McLeod HL. Clinically relevant drug-drug interactions in oncology. Br J Clin Pharmacol. 1998; 45:539-44.
19. Moosa A, Dobish R, Watts C. Interacting with drugs used in oncology: an Alberta Cancer Board initiative. J Oncol Pharm Pract. 2003; 9:87-107.
20. Loadman PM, Bibby MC. Pharmacokinetic drug interactions with anticancer drugs. Clin Pharmacokinet. 1994; 26:486-500.
21. Van Meerten E, Verweij J, Schellens JH. Antineoplastic agents. Drug interactions of clinical significance. Drug Saf. 1995; 12:168-82.
22. Lam MS, Ignoffo RJ. A guide to clinically relevant drug interactions in oncology. J Oncol Pharm Pract. 2003; 9:45-85.
23. Beijnen JH, Schellens JH. Drug interactions in oncology. Lancet Oncol. 2004; 5:489-96.
24. Sparreboom A, Cox MC, Acharya MR et al. Herbal remedies in the United States: potential adverse interactions with anticancer agents. J Clin Oncol. 2004; 22:2489-503.
25. Figoli F, Sileni VC. Leucovorin calcium enhancement of mucositis after continuous infusion fluorouracil and short infusion cisplatin. J Clin Oncol. 1989; 7:680-1.
26. Advanced Colorectal Cancer Meta-Analysis Project. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J Clin Oncol. 1992; 10:896-903.
27. Grogan L, Sotos GA, Allegra CJ. Leucovorin modulation of fluorouracil. Oncology. 1993; 7:63-72.
28. Okuda H, Nishiyama T, Ogura Y et al. Lethal drug interactions of sorivudine, a new antiviral drug, with oral 5-fluorouracil prodrugs. Drug Metab Dispos. 1997; 25:270-3.
29. Okuda H, Ogura K, Kato A et al. A possible mechanism of eighteen patient deaths caused by interactions of sorivudine, a new antiviral drug, with oral 5-fluorouracil prodrugs. J Pharmacol Exp Ther. 1998; 287:791-9.
30. Fox RM, Woods RL, Tattersall MH et al. Allopurinol modulation of 5-fluorouracil toxicity. Cancer Chemother Pharmacol. 1981; 5:151-5.
31. Kroener JF, Saleh F, Howell SB. 5-Fluorouracil and allopurinol: toxicity modulation and phase II results in colon cancer. Cancer Treat Rep. 1982; 66:1133-7.
32. Howell SB, Wung WE, Taetle R et al. Modulation of 5-fluorouracil toxicity by allopurinol in man. Cancer. 1981; 48:1281-9.
33. Woolley PV, Ayoob MJ, Smith FP et al. A controlled trial of the effect of 4-hydroxypyrazolopyrimidine (allopurinol) on the toxicity of a single bolus dose of 5-fluorouracil. J Clin Oncol. 1985; 3:103-9.
34. Harvey VJ, Slevin ML, Dilloway MR et al. The influence of cimetidine on the pharmacokinetics of 5-fluorouracil. Br J Clin Pharmacol. 1984; 18:421-30.
35. Mainwaring P, Grygiel JJ. Interaction of 5-FU with folates. Aust N Z J Med. 1995; 25:60.
36. Desai AA, Vogelzang NJ, Rini BI et al. A high rate of venous thromboembolism in a multi-institutional Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil and daily thalidomide in patients with metastatic renal cell carcinoma. Cancer. 2002; 95:1629-36.
37. Orr LE. Potentiation of myelosuppression from cancer chemotherapy and thiazide diuretics. Drug Intell Clin Pharm. 1981; 15:967-70.
38. Wajima T, Mukhopadhyay P. Possible interactions between warfarin and 5-fluorouracil. Am J Hematol. 1992; 40: 238. Letter.
39. Chlebowski RT, Gota CH, Chan KK et al. Clinical and pharmacokinetic effects of combined warfarin and 5-fluorouracil in advanced colon cancer. Cancer Res. 1982; 42:4827-30.
40. Scarfe MA, Israel MK. Possible drug interaction between warfarin and combination of levamisole and fluorouracil. Ann Pharmacother. 1994; 28:464-7.
41. Brown MC. An adverse interaction between warfarin and 5-fluorouracil: a case report and review of the literature. Chemotherapy. 1999; 45:392-5.
42. Kolesar JM, Johnson CL, Freeberg BL et al. Warfarin-5 FU interaction - a consecutive case series. Pharmacotherapy. 1999; 19:1445-9.
43. Aki Z, Kotiloglu G, Ozyilkan O. A patient with a prolonged prothrombin time due to an adverse interaction between 5-fluorouracil and warfarin. Am J Gastroenterol. 2000; 95:1093-4.
44. Moertel CG, Fleming TR, MacDonald JS et al. Hepatic toxicity associated with fluorouracil and levamisole adjuvant therapy. J Clin Oncol. 1993; 11:2386-90.
45. Bardakji Z, Jolivet J, Langelier Y et al. 5-Fluorouracil-metronidazole combination therapy in metastatic colorectal cancer-clinical, pharmacokinetic and in vitro cyto-toxicity studies. Cancer Chemother Pharmacol. 1986; 18:140-4.
46. McDermott BJ, Van den Berg HW, Martin WM et al. Pharmacokinetic rationale for the interaction of 5-fluorouracil and misonidazole in humans. Br J Cancer. 1983; 48:705-10.
47. Brickell K, Porter D, Thompson P. Phenytoin toxicity due to fluoropyrimidines (5FU/capecitabine): three case reports. Br J Cancer. 2003; 89:615-6.
48. Gilbar PJ, Brodribb TR. Phenytoin and fluorouracil interaction. Ann Pharmacother. 2001; 35:1367-70.
49. Grem JL, Chu E, Boardman D et al. Biochemical modulation of fluorouracil with leucovorin and interferon: preclinical and clinical investigations. Semin Oncol. 1992; 19(S3):36-44.
50. Schuller J, Czejka MJ, Schernthaner G et al. Influence of interferon alpha-2b with or without folinic acid on pharmacokinetics of fluorouracil. Semin Oncol. 1993; 19(S3):93-7.
51. Seymour MT, Patel N, Johnston A et al. Lack of effect of interferon alpha-2A upon 5-fluorouracil pharmacokinetics. Br J Cancer. 1994; 70:724-8.
52. Pritchard K, Paterson AH, Paul NA et al. Increased thromboembolic complications with concurrent tamoxifen and chemotherapy in a randomized trial of adjuvant therapy for women with breast cancer. J Clin Oncol. 1996; 14:2731-7.
53. Bruckner HW, Creasey WA. The administration of 5-fluorouracil by mouth. Cancer. 1974; 33:14-8.
54. Trump DL, Egorin MJ, Forrest A et al. Pharmacokinetic and pharmacodynamic analysis of fluorouracil during 72-hour continuous infusion with and without dipyridamole. J Clin Oncol. 1991; 9:2027-35.
55. Grem JL. Biochemical modulation of fluorouracil by dipyridamole: preclinical and clinical experience. Semin Oncol. 1992; 19:56-65.
56. Joly AC, Monnet I, Chouaid C et al. Continuous infusion of 5-fluorouracil and non-small cell lung cancer (NSCLC): circadian rhythms and influence of a corticotherapy. In: Proceedings of the 28th European Symposium on Clinical Pharmacy. Brussels: European Society of Clinical Pharmacy; 1991: Abstract 195.
57. DiPalm JR, McMichael R. The interaction of vitamins with cancer chemotherapy. Cancer. 1979; 29:280-6.
58. Roberts JS, Watrous ML, Schulz RM et al. Quantifying the clinical significance of drug-drug interactions: scaling pharmacists' perception of a common interactions classification scheme. Ann Pharmacother. 1996; 30:926-34.
59. Van Roon EN, Kerremans AL, Flikweert S et al. Structured assessment of the relevance of drug-drug interactions. Naunyn Schmiedebergs Arch Pharmacol. 2003; 367(S1):R143. Abstract.
60. Jansman FG, Sleijfer DT, de Graaf JC et al. Management of chemotherapy-induced adverse effects in the treatment of colorectal cancer. Drug Saf. 2001; 24:353-67.